MRKH Syndrome: Causes, Symptoms & Treatment

What Is MRKH Syndrome?

Mayer-Rokitansky-Küster-Hauser syndrome (MRKH syndrome) is a rare congenital disorder affecting the female reproductive tract. Women with MRKH syndrome have a normal female chromosomal makeup (46,XX) and functional ovaries, but the uterus and the upper part of the vagina are either completely absent or only rudimentarily (incompletely) developed. The condition is also known as Müllerian agenesis or Müllerian aplasia, as it results from the failure of the Müllerian ducts to develop properly during early fetal life.

MRKH syndrome affects approximately 1 in 4,500 to 5,000 female newborns, making it one of the most common congenital anomalies of the female reproductive system.

Types of MRKH Syndrome

Two main types are recognized:

• Type I (isolated): Only the Müllerian duct-derived structures are affected, meaning the uterus and upper vagina are absent or underdeveloped, without additional anomalies.
• Type II (MURCS association): Additional malformations are present, such as kidney anomalies (renal agenesis), spinal defects (vertebral fusions), or hearing loss (ossicle malformations). MURCS stands for Müllerian duct aplasia, Renal aplasia, and Cervicothoracic Somite anomalies.

Causes

The exact cause of MRKH syndrome is not yet fully understood. It results from a developmental disruption during early embryogenesis, approximately between weeks 6 and 12 of pregnancy, when the Müllerian ducts fail to develop into the uterus, fallopian tubes, and upper vagina.

In some cases, genetic variants have been identified, including mutations in genes such as WNT4, LAMC1, and HNF1B. The condition usually occurs sporadically, though familial clustering has also been reported.

Symptoms

Because the ovaries function normally, hormonal development and secondary sexual characteristics (breast development, pubic hair) are typically unaffected. The key signs and symptoms include:

• Absence of the first menstrual period (primary amenorrhea) despite otherwise normal pubertal development
• Absent or very shallow vagina
• Inability to become pregnant naturally (infertility)
• Possible pain during sexual intercourse (dyspareunia) due to a shortened vaginal canal
• In Type II: additional symptoms depending on associated anomalies (e.g., kidney dysfunction, hearing difficulties)

Diagnosis

The diagnosis is typically made during adolescence when the first menstrual period does not occur. The diagnostic workup includes:

• Gynecological examination: Assessment of the external genitalia and vaginal opening
• Ultrasound (sonography): Visualization of pelvic organs; the uterus is not detectable
• MRI (magnetic resonance imaging): Detailed imaging to assess rudimentary uterine structures and associated anomalies
• Chromosomal analysis (karyotype): Confirmation of the normal female karyotype 46,XX
• Hormone levels: Typically within normal range, as the ovaries are functional
• Renal ultrasound: To rule out kidney abnormalities, especially in suspected Type II

Treatment

There is no cure that restores the missing structures. Treatment focuses on improving quality of life and enabling sexual function:

Vaginal Dilation Therapy (Non-Surgical)

The Frank method, or dilator therapy, is the preferred first-line treatment. Gradual, gentle pressure using dilators (smooth rods of increasing size) is applied regularly to create a functional neovagina. This non-surgical approach is safe and, with consistent use, achieves excellent outcomes.

Surgical Options

If dilation therapy is unsuccessful or declined, surgical procedures are available:

• Vecchietti procedure: A minimally invasive technique that creates a neovagina by progressively stretching the vaginal tissue using a traction device
• McIndoe procedure: Surgical creation of a neovagina using a skin graft or biological material to line the newly formed canal
• Davydov procedure: Use of peritoneum (abdominal lining) to create and line the neovagina

Uterus Transplantation

Specialized centers have performed uterus transplantation procedures, allowing some affected women to carry a pregnancy. However, this remains an experimental approach and is not yet widely available.

Family Building and Fertility Options

Since women with MRKH syndrome have functioning ovaries, their own eggs can be retrieved. In countries where surrogacy or egg donation is legally permitted, assisted reproductive options exist. Adoption is also a pathway to parenthood.

Psychological Support

The diagnosis can be emotionally overwhelming. Psychological counseling and peer support through MRKH patient networks and support groups are an essential part of comprehensive care.

References

1. Morcel K, Camborieux L, Guerrier D. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. Orphanet Journal of Rare Diseases. 2007;2:13. DOI: 10.1186/1750-1172-2-13.
2. American College of Obstetricians and Gynecologists (ACOG). Müllerian Agenesis: Diagnosis, Management, and Treatment. Committee Opinion No. 562. 2013.
3. Herlin MK, Petersen MB, Bränner M. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update. Orphanet Journal of Rare Diseases. 2020;15(1):214. DOI: 10.1186/s13023-020-01491-9.